OR

Oric Pharmaceuticals IncNASDAQ ORIC Stock Report

Last reporting period 30 Sep, 2023

Updated 12 Nov, 2024

Last price

Market cap $B

0.758

Micro

Exchange

XNAS - Nasdaq

ORIC Stock Analysis

OR

Uncovered

Oric Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.758

Dividend yield

Shares outstanding

45.091 B

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 86 full-time employees. The company went IPO on 2020-04-24. The company is engaged in improving patients' lives by Overcoming Resistance In Cancer. The company is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. ORIC-114, is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations. ORIC-944 is an allosteric inhibitor of the polycomb repressive complex 2 (PRC2).

View Section: Eyestock Rating